Substituted tetrahydro-quinoline-sulfonamide compounds,...

Details Substituted tetrahydro-quinoline-sulfonamide compounds,... Substituted tetrahydro-quinoline-sulfonamide compounds,...

2011-06-21

2011-06-21

Bernhardt, Emily (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S363000

Reexamination Certificate

active

07964603

ABSTRACT:
The present invention refers to substituted tetrahydro-quinoline-sulfonamide compounds of general formula (I):a method for their preparation, a medicament comprising these compounds and the use of substituted tetrahydro-quinoline-sulfonamide compounds for the preparation of medicaments for 5-HT6receptor regulation as well as for the treatment of disorders related thereto.

REFERENCES:
patent: 6423717 (2002-07-01), Bromidge et al.
patent: 6727270 (2004-04-01), Kelly et al.
patent: 6737426 (2004-05-01), Gericke et al.
patent: 6770642 (2004-08-01), Cole et al.
patent: 7144883 (2006-12-01), Caldirola et al.
patent: 7572787 (2009-08-01), Caldirola et al.
patent: 7655690 (2010-02-01), Merce Vidal et al.
patent: WO 96/02537 (1996-02-01), None
patent: WO 96/11929 (1996-04-01), None
patent: WO 96/23783 (1996-08-01), None
patent: WO 97/08167 (1997-03-01), None
patent: WO2004/078176 (2004-09-01), None
patent: WO2005/014552 (2005-02-01), None
patent: WO2006/053785 (2005-11-01), None
patent: WO2007/025798 (2007-03-01), None
patent: WO2007/032572 (2007-03-01), None
Wolff, Manfred E. Burger's Medicinal Chemistry, 5th Ed. Part 1, pp. 975-977 (1995).
Banker et al. “Modern Pharmaceutics”, 3rd Ed. p. 596 (1996).
Vippagunta et al. Advanced Drug Delivery Reviews, vol. 48, p. 3-26 (2001).
Robichaud et al. In Annual Reports in Medicinal Chemistry, vol. 36, p. 11-20 (2000).
Robichaud et al. In Annual Reports in Medicinal Chemistry, vol. 36, p. 11-20 (2000).
Rogers et al. Psychopharmacology, vol. 158, p. 114-119 (2001).
Bromidge et al. Bioorganic & Medicinal Chemistry Letters, vol. 11, p. 55-58 (2001).
Tariska et al. Orv. Hetil, vol. 141(22), pp. 1189-1193 (2000) (Abstract provided).
Bourson, et al, “Involvement of 5-HT6receptors in nigro-striatal function in rodents”Brit. J. Pharmacology(1998) 125: 1562-1566.
Bourson, et al, “Detemination of the Role of the 5-ht6Receptor in the Rat Brain: A Study using Antsense Oligonucleotides”J. Pharmacol. Exp. Ther. (1996) 274(1): 173-180.
Bradbury, et al., “Muscarinic Receptor Binding and Activation of Second Messengers by SubstitutedN-Methyl-N-[4-(1-azacycloalkyl)-2-butynyl]acetamides”J. Med. Chem. (1991) 34: 1073-1079.
Branchek, et al., “5-HT6Receptors as Emerging Targets for Drug Discovery”,Annu. Rev. Pharmacol. Toxlcol. (2000) 40: 319-334.
Choi, et al., “A Facile Debromination Reaction: Can Bromide Now Be Used as a Protective Group in Aromatic Systems?”J. Am. Chem. Soc. (2001) 123: 9202-9203.
Fix, Joseph, “Oral Drug Delivery, Small Intestine & Colon”Encyclopedia of Controlled Drug Delivery, vol. 2, Mathiowitz, E. (Ed.), John Wiley & Sons, Inc., New York (1999) 698-728.
Gilbert, Everett E., “Recent Developments in Preparative Sulfonation and Sulfation”,Synthesis(Sep. 1969) 1: 3-10.
Hoyer D. and Martin, G., “5-HT6Receptor Classification and Nomenclature: Towards a Harmonization with the Human Genome”Neuropharmacology(1997) 36(4/5): 419-428.
Kajigaeshi, et al., “Halogenation Using Quaternary Ammonium Polyhalides. XI.1)Bromination of Acetanilides by Use of Tetraalkylammonium Polyhalides”Chem. Soc. Of Japan(Jul. 1988) 61: 2681-2683.
Kohen, et al., “Cloning, Characterization, and Chromosomal Localization of a Human 5-HT6Serotonin Receptor”J. of Neurochemistry(1996) 66(1): 47-56.
Monsma, et al., “Cloning and Expression of a Novel Serotonin Receptor with High Affinity for Tricyclic Psychotropic Drugs”Molecular Pharmacology(1993) 43: 320-327.
Munson, Peter J., and Rodbard, D., “Ligand: A Versatile Computerized Approach for Characterization of Ligand-Binding Systems”Analytical Biochemistry(1980) 107: 220-239.
Nose, A. and Kudo, T., “Reduction of Heterocyclic Compounds. II.1)Reduction of Heterocyclic Compounds with Sodium Borohydride-Transition Metal Salt Systems”Chem. Pharm. Bull. (1984) 32(6): 2421-2425.
Rogers, et al., “Cognitive Enhancement Effects of the Selective 5-HT6Antagonist SB-271046”Br. J. Pharmacol. Suppl. (1999) 127: 22.
Roth, et al., “Binding of Typical and Atypical Antipsychotic Agents to 5-Hydroxytryptamine-6 and 5-Hydroxytryptamine-7 Receptors”J. Pharmacol. Exp. Ther. (1994) 268: 1403-1410.
Routledge, et al., “Characterization of SB-271046: A potent, selective and orally active 5-HT6receptor antagonist”Br. J. Pharm. (2000) 130: 1606-1612.
Ruat, et al, “A Novel Rat Serotonin (5-HT6) Receptor: Molecular Cloning Localization and Stimulation of cAMP Accumulation”Biochemical and Biophysical Research Communications(1993) 193(1): 268-276.
Sarvari, M.H., and Sharghi, H., “Zinc oxide (ZnO) as a new, highly efficient, and reusable catalyst for acylation of alcohols, phenols and amines under solvent free conditions”Tetrahedron(2005) 61: 10903-10907.
Sleight, et al., “Effects of altered 5-ht6expression in the rat: functional studies using antisense oligonucleotids”Behavioural Brain Research(1996) 73: 245-248.
Smid, et al., “Synthesis, Structure—Activity Relationships, and Biological Properties of 1-Heteroary1-4-[ω-(1H-indol-3-yl)alkyl]piperazines, Novel Potential Antipsychotics Combining Potent Dopamine D2Receptor Antagonism with Potent Serotonin Reuptake Inhibition”J. Med. Chem. (2005) 48: 6855-6869.
Takada, K. and Yoshikawa, H., “Oral Drug Delivery”, vol. 2, Mathiowitz, E. (Ed.), John Wiley & Sons, Inc., New York (1999) 728-742.
Woolley, et al., “A role for 5-ht6receptors in retention of spatial learning in the Morris water maze”Neurophamacology(2001) 41: 210-219.
Yoshioka, et al, “Central Distribution and Function of 5-ht6Receptor Subtype in the Rat Brain”Ann. NY Acad. Sci. (1998) 861: 244.
European Search Report, dated Nov. 16, 2007, issued in European Patent Application No. EP 07 38 0216.
Caldirola, Patrizia, “5-HT6Receptor Antagonism: A Novel Mechanism for the Management of Obesity” Power Point presentation atObesity and Related Disorders Conference, The Hatton, Feb. 17, 2003, (pp. 1-25).
Da Silva Costa, et al, “Selective 5-HT6Receptor Blockade Improves Spatial Recognition Memory and Reverses Age-Related Deficits in Spatial Recognition Memory in the Mouse”Neuropsychopharmacology(2008) pp. 1-12.
Fisas, et al., “Chronic 5-HT6receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats”Brit. J. Pharmacology(2006) 148: 973-983.
Foley, et al., “The 5-HT6Receptor Antagonist SB-271046 Reverses Scopolamine-Disrupted Consolidation of a Passive Avoidance Task and Ameliorates Spatial Task Deficits in Aged Rats”Neuropsychopharmacology(2004) 29: 93-100.
Foley, et al., “The selective 5-HT6receptor antagonists SB-271046 and SB-399885 potentiate NCAM PSA immunolabeling of dentate granule cells, but not neurogenesis, in the hippocampal formation of mature Wistar rats”Neuopharmacology(2008) 54: 1165-1174.
Fone, Kevin C.F., “An update on the of the 5-hydroxytrptamine6receptor in cognitive function”Neuropharmacology(2008) 55: 1015-1022.
Greene, T.W. and Wuts, P.G.M., “Protective Groups in Organic Chemistry”, 2nd, John Wiley & Sons, (1999) (Table of Contents Only).
Halford, et al., “Serotonergic Drugs: Effects on Appetite Expression and Use for the Treatment of Obesity”Drugs(2007) 67(1): 27-55.
Holenz, et al., “Medicinal chemistry strategies to 5-HT6receptor ligands as potential cognitive enhancers and antiobesity agents”Drugs Discovery Today(2006) 11: 283-299.
Johnson, et al., “5-HT6receptor antagonists: Prospects for the treatment of cognitive disorders including dementia”Current Opinion in Drug Discovery&Development(2008) 11(5): 642-654.
King, et al., “5-HT6receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation—an effect sensitive to NMDA receptor antagonis

Affiliated with

Also associated with

Rating

Substituted tetrahydro-quinoline-sulfonamide compounds,... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted tetrahydro-quinoline-sulfonamide compounds,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted tetrahydro-quinoline-sulfonamide compounds,... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2708805